The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expression of B7-H3 (CD276) in surgically resected esophageal squamous cell carcinoma.
 
Yuta Maruki
No Relationships to Disclose
 
Atsuo Takashima
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical
Research Funding - Gilead Sciences (Inst); LSK BioPharma (Inst); MSD (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Takahiro Miyamoto
No Relationships to Disclose
 
Hidekazu Hirano
No Relationships to Disclose
 
Hirokazu Shoji
No Relationships to Disclose
 
Yoshitaka Honma
Research Funding - AstraZeneca; Daiichi Sankyo; Merck Serono; Teijin Pharma
 
Satoru Iwasa
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst)
 
Natsuko Okita
Research Funding - Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Ken Kato
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - MSD Oncology; Ono Pharmaceutical; Shionogi
 
Shigeki Sekine
No Relationships to Disclose
 
Kazuo Koyanagi
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Shigehisa Kitano
Consulting or Advisory Role - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Meiji Seika Kaisha; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Regeneron (Inst)
 
Kazunori Aoki
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)